Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

520
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
520
Odds Ratio01:09

Odds Ratio

2.2K
The odds ratio (OR) is a statistical measure used extensively in epidemiology and research to quantify the strength of association between exposure and outcome across different groups. Unlike relative risk, which compares the probabilities of an event occurring, the odds ratio compares the odds of an event occurring in the exposed group to the odds of it occurring in the unexposed group. The odds, in this context, are calculated as the probability of the event happening divided by the...
2.2K
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

697
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
697
Decision Making: P-value Method01:09

Decision Making: P-value Method

7.1K
The process of hypothesis testing based on the P-value method includes calculating the P- value using the sample data and interpreting it.
First, a specific claim about the population parameter is proposed. The claim is based on the research question and is stated in a simple form. Further, an opposing statement to the claim  is also stated. These statements can act as null and alternative hypotheses:  a null hypothesis would be a neutral statement while the alternative hypothesis can...
7.1K
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

312
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
312
Variability: Analysis01:11

Variability: Analysis

619
Measures of variability are statistical metrics that reveal the dispersion pattern within a dataset. They are pivotal in biostatistics, providing insights into the heterogeneity within health and biological data. Variability signifies the degree to which data points diverge from one another, helping researchers understand the potential range of values and associated uncertainty within the data.
The range is a simple measure of variability, indicating the difference between the highest and...
619

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic Risk Factors for Kidney Function in Individuals with Type 1 Diabetes.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Differences Between Glycemia Estimates from Hemoglobin A1c and Continuous Glucose Monitoring and Their Association with Complete Blood Counts.

Diabetes technology & therapeutics·2025
Same author

Differential Longitudinal Effects of Glucose-Lowering Medications on Glucagon and C-peptide Responses in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).

Diabetes care·2025
Same author

Cardiovascular autonomic neuropathy defined by indices of heart rate variability is associated with cardiovascular disease: a longitudinal cohort study of participants with type 1 diabetes.

Cardiovascular diabetology·2025
Same author

The NIDDK Takes on the Complications of Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study.

Diabetes care·2025
Same author

Identification and mitigation of a systematic analysis error in a multicenter dual-energy x-ray absorptiometry study.

Clinical trials (London, England)·2025

Related Experiment Video

Updated: Mar 21, 2026

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
07:05

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

6.5K

Probabilistic measures of cost-effectiveness.

Ionut Bebu1, Thomas Mathew2, John M Lachin1

  • 1The Biostatistics Center, Department of Epidemiology and Biostatistics, The George Washington University, 6110 Executive Blvd., Rockville, 20852, MD, U.S.A.

Statistics in Medicine
|May 20, 2016
PubMed
Summary
This summary is machine-generated.

This study introduces probability-based measures for assessing treatment cost-effectiveness. Generalized pivotal quantities and U-statistics offer accurate confidence intervals for these measures, aiding clinical trial analysis.

Keywords:
U-statisticscost-effectivenessgeneralized pivotal quantityincremental cost effectiveness ratio (ICER)incremental net benefit (INB)

More Related Videos

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods
13:04

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods

Published on: September 19, 2012

12.5K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.5K

Related Experiment Videos

Last Updated: Mar 21, 2026

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
07:05

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

6.5K
Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods
13:04

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods

Published on: September 19, 2012

12.5K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.5K

Area of Science:

  • Biostatistics
  • Health Economics
  • Clinical Trial Analysis

Background:

  • Cost-effectiveness analysis (CEA) is crucial for healthcare decision-making.
  • Existing CEA methods may lack flexibility in handling cost and effectiveness measures.
  • Probability-based measures offer a robust approach to CEA.

Purpose of the Study:

  • To introduce novel probability-based measures for assessing treatment cost-effectiveness.
  • To investigate the interval estimation of these measures using parametric and non-parametric approaches.
  • To evaluate the performance of different statistical methods for confidence interval computation.

Main Methods:

  • Development of probability-based measures invariant under monotone transformations.
  • Application of the delta method and generalized pivotal quantity approach under bivariate normality.
  • Utilization of a non-parametric U-statistics-based approach for confidence intervals.

Main Results:

  • Generalized pivotal quantities provide accurate confidence interval coverage under bivariate normality.
  • Non-parametric U-statistics-based methods are accurate for moderately large sample sizes.
  • The proposed measures and methods were illustrated using prostate cancer therapy clinical trial data.

Conclusions:

  • The introduced probability-based measures enhance cost-effectiveness analysis flexibility.
  • Generalized pivotal quantities and U-statistics are reliable methods for interval estimation in CEA.
  • These statistical advancements support evidence-based healthcare decisions and clinical trial interpretation.